| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2021―Jun―18 |
Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes |
S Sahana, Ambily Sivadas, Mohit Mangla, Abhinav Jain, Rahul C Bhoyar, Kavita Pandhare, Anushree Mishra, Disha Sharma, Mohamed Imran, Vigneshwar Senthivel, Mohit Kumar Divakar, Mercy Rophina, Bani Jolly, Arushi Batra, Sumit Sharma, Sanjay Siwach, Arun G Jadhao, Nikhil V Palande, Ganga Nath Jha, Nishat Ashrafi, Prashant Kumar Mishra, AK Vidhya, Suman Jain, Debasis Dash, Nachimuthu Senthil Kumar, Andrew Vanlallawma, Ranjan Jyoti Sarma, Lalchhandama Chhakchhuak, Shantaraman Kalyanaraman, Radha Mahadevan, Sunitha Kandasamy, Pabitha Devi, Raskin Erusan Rajagopal, J Ezhil Ramya, P Nirmala Devi, Anjali Bajaj, Vishu Gupta, Samatha Mathew, Sangam Goswami, Savinitha Prakash, Kandarp Joshi, Meya Kumla, S Sreedevi, Devarshi Gajjar, Ronibala Soraisham, Rohit Yadav, Yumnam Silla Devi, Aayush Gupta, Mitali Mukerji, Sivaprakash Ramalingam, BK Binukumar, Sridhar Sivasubbu, Vinod Scaria |
| 2 |
[GO] |
2021―Mrz―24 |
Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in coronavirus disease-2019 patients |
Mohitosh Biswas |
| 3 |
[GO] |
2020―Nov―27 |
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2 mediated SARS-CoV-2 entry |
Georgia Ragia, Vangelis G Manolopoulos |
| 4 |
[GO] |
2020―Jun―10 |
Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing? |
Elissar Moujaess, Hampig Raphael Kourie, Joseph Kattan |
| 5 |
[GO] |
2020―Jun―05 |
Angiotensin converting enzyme 2 (ACE2) and COVID-19: using antihypertensive medications, pharmacogenetic considerations |
Eric M Snyder, Bruce D Johnson |
|
